– USA, MA – Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, today announced the appointment of Dr. Theresa Heah (M.D.) as CEO, succeeding Dr. Michael Ehlers who will become Chair of the Board of Directors.
“We’re thrilled to welcome Theresa, and I look forward to working with her to advance Intergalactic’s proprietary platform and deliver groundbreaking treatments to patients.” said Dr. Michael Ehlers.
About Dr. Theresa G.H. Heah
Dr. Heah brings extensive experience in deal-making, research, development, and commercialization of gene therapy and ophthalmic products on a global scale and will lead Intergalactic as it enters its next phase of growth, with an initial focus on ophthalmology.
Dr. Heah is an accomplished executive with over two decades of drug development and commercial experience, focused primarily on gene therapy and ophthalmology. She most recently served as President and CMO at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy and supporting the company’s Series C financing. Before joining Kriya, Dr. Heah served as EVP of Operations and CMO at AsclepiX Therapeutics, where she led the company’s Series A financing and advancement of its pipeline products into the clinic.
Dr. Heah also previously served as CMO at Applied Genetic Technologies Corporation (AGTC), working to develop gene therapies in ophthalmology and rare diseases. In addition, she has held several leadership positions with increasing responsibility in early-stage private companies (Fovea Pharmaceuticals) and publicly traded companies (Aerie Pharmaceuticals, Allergan, Bayer Healthcare, Sanofi).
“Non-viral gene therapy is an exciting area that holds immense untapped potential,” said Dr. Theresa Heah. “The transformational approach being advanced by Intergalactic has the promise to expand the gene therapy universe and bring meaningful change to patients in need. I’m honored to be joining this exceptional company and am looking forward to sharing new data soon that demonstrate the promise of Intergalactic’s unique platform to address major unmet needs for patients with ophthalmological disorders and beyond.”
Dr. Heah earned her M.D. from Guy’s, King’s, and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin.
About Michael Ehlers
Dr. Michael Ehlers, who is CSO and Venture Partner of Apple Tree Partners was the founding CEO of Intergalactic Therapeutics and led its incubation.
As Board Chair, Dr. Ehlers brings his deep scientific and business expertise to Intergalactic Therapeutics. Before joining ATP, Dr. Ehlers was head of R&D at Biogen and, before that, headed Neuroscience and Rare Disease R&D at Pfizer. At ATP, he has led investments in ATP portfolio companies including Ascidian Therapeutics, Aulos Bioscience, Intergalactic Therapeutics, and Replicate Bioscience.
Dr. Ehlers earned a B.S. degree from the California Institute of Technology and held M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.
Intergalactic Therapeutics, an ATP company, is transforming medicine through non-viral gene therapy. Its proprietary integrated platform comprises three core pillars: versatile C3DNA technology (covalently closed and circular DNA); groundbreaking customized approaches to local therapeutic delivery using COMET pulsed electric field system; and a rapid, scalable, and cost-effective manufacturing process to make gene therapy safer and more accessible. With a diversified portfolio of potential new treatments for eye diseases and beyond, Intergalactic is dedicated to helping patients around the world by bringing non-viral gene therapies into reality.
For more information, visit www.intergalactictx.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
